Sionna Therapeutics, Inc. Common Stock SION

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

• Zacks Investment Research 16 sept

  SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

  Sionna Therapeutics announced a 46% workforce reduction and major restructuring following the failure of SION-719 to meet its primary endpoint in a cystic fibrosis study. The company is shifting focus to its dual combination therapy SION-451 + SION-2222, which it plans to advance into phase IIa trials in 2027. The restructuring is expected to extend cash runway into the second half of 2029.

  

• GlobeNewswire Inc. 2 sept

  SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

  Law firm Bragar Eagel & Squire is investigating Sionna Therapeutics after the company announced its SION-719 Phase 2a trial failed to achieve its primary endpoint for sweat chloride reduction. The stock price fell over 91% following the announcement. The firm is encouraging affected shareholders to contact them regarding potential securities law violations.

  

• GlobeNewswire Inc. 26 ago

  Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  Glancy Prongay Wolke & Rotter LLP is investigating Sionna Therapeutics for potential securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, prompting a class action lawsuit on behalf of affected shareholders.

  

• GlobeNewswire Inc. 25 ago

  Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION)  Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  The Law Offices of Frank R. Cruz is investigating Sionna Therapeutics for potential federal securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, causing significant investor losses.

  

• GlobeNewswire Inc. 25 ago

  Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  Law Offices of Howard G. Smith is investigating potential securities fraud violations at Sionna Therapeutics, Lincoln Educational Services, and Flotek Industries on behalf of shareholders who suffered losses. Sionna's stock plummeted 91.2% following disappointing Phase 2a trial results and a decision not to advance its lead candidate.